Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage

I. Chin Wu, Ching Lung Lai, Steven Huy Bui Han, Kwang Hyup Han, Stuart C. Gordon, You Chen Chao, Chee Kiat Tan, William Sievert, Tawesak Tanwandee, Dong Xu, Boon Leong Neo, Ting Tsung Chang

    Research output: Contribution to journalArticle

    36 Scopus citations

    Abstract

    Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 × upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that significant hepatic necroinflammation and fibrosis were present in a substantial proportion of patients with ALT 1 to 2×ULN. To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-naïve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2×ULN. A total of 1347 patients were randomized to treatment with entecavir or lamivudine. Three hundred thirty-six patients, constituting 25% of the total study population, had screening and baseline ALT 1.3 to 2 × ULN. Clinically significant necroinflammation (Knodell necroinflammation score >7) was observed in 60% and 72% of hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients, respectively, whereas marked fibrosis (Ishak fibrosis score >4) was observed in 8% and 15% of HBeAg-positive and HBeAg-negative patients, respectively. Among entecavir-treated HBeAgnegative patients, the proportions of patients achieving histological improvement, HBV DNA <300 copies/mL, and ALT normalization were similar between patients with mildly elevated ALT and those with ALT>2×ULN. However, entecavir-treated HBeAg-positive patients with mildly elevated ALT had lower response rates for histological improvement,HBVDNAless than 300 copies/mL, ALT normalization, and HBeAg seroconversion than those with ALT greater than 2×ULN. Conclusion: This retrospective analysis demonstrated that HBeAg-negativeCHB patients treated with entecavir responded similarly irrespective of baseline ALT level. However, HBeAg-positive patients with mildly elevated ALT responded less well to treatment with entecavir than did those with ALT greater than 2 × ULN.

    Original languageEnglish (US)
    Pages (from-to)1185-1189
    Number of pages5
    JournalHepatology
    Volume51
    Issue number4
    DOIs
    StatePublished - Apr 1 2010

      Fingerprint

    ASJC Scopus subject areas

    • Hepatology

    Cite this

    Wu, I. C., Lai, C. L., Bui Han, S. H., Han, K. H., Gordon, S. C., Chao, Y. C., Tan, C. K., Sievert, W., Tanwandee, T., Xu, D., Neo, B. L., & Chang, T. T. (2010). Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology, 51(4), 1185-1189. https://doi.org/10.1002/hep.23424